Abstract: The present invention provides methods used to condition recipients of organ transplants to achieve tolerance using a novel non-myeloablative conditioning regime featuring total lymphoid irradiation (TLI) and total body irradiation (TBI), each provided as a fractionated series of doses. Advantageously, this regime not only provides better conditioning than existing non-myeloablative regimes, but also does not require extending the typical duration of the conditioning course.

Abstract: A moiré pattern imaging device includes a light-transmissive film and a light-shielding film. The light-transmissive film includes a plurality of imaging units and a light-incident surface and a light-emergent surface opposite to each other. The plurality of imaging units are disposed on the light-incident surface, the light-emergent surface, or a combination thereof and are arranged in two dimensions to form an imaging unit array. The light-shielding film includes a plurality of light-transmissive regions. The light-transmissive regions are arranged in two dimensions to form a light-transmissive array, and the light-shielding film is overlaid on the light-incident surface or the light-emergent surface. The light-transmissive array corresponds to the imaging unit array. The imaging unit array and the light-transmissive array together form a moiré pattern effect to generate an image magnification effect.

Abstract: Interferon-alpha (IFN?) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and/or antitumor agents. In one embodiment, the IFN? analog protein has an amino acid sequence that differs from a native human IFN? interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN?) protein. Methods of combination therapy are also described.

Abstract: Interferon-alpha (IFN?) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFN? analog protein has an amino acid sequence that differs from a native human IFN? interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN?) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFN? analog protein are also described.

Abstract: A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events.

Abstract: The present invention relates to a “structure of lamp socket in lamp string”, particularly for one having contrivance of (elastic plate) and (electric conducting plate) so that the rest (illuminant elements) in the lamp string can maintain illuminating and glittering even falling off of any (illuminant elements).

Abstract: A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFN?) at a dose sufficient to increase the IL-10 level.

Abstract: Methods of modulating cytokine levels in a human subject by administering interferon-tau (IFN?) are described. More specifically, a method of up-regulating the interleukin 10 (IL-10) level in patients afflicted with a condition that responds to treatment by having an increased blood IL-10 level, such as an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN? is described. Also described are methods of modulating blood levels of interleukin-12 (IL-12) and interferon-gamma (IFN-?) by administering IFN?. In various embodiments, IFN? is administered alone or in combination with a second therapeutic agent.

Abstract: Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.

Abstract: Interferon-alpha (IFN?) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antivial and/or antitumor agents. In one embodiment, the IFN? analog protein has an amino acid sequence that differs from a native human IFN? interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN?) protein. Methods of combination therapy are also described.

Abstract: A composition for use in preparation of a medicament for treating a condition responsive to interferon therapy in a human subject is described. The composition includes interferon-tau in dosage form suitable for oral administration to the intestinal tract in an amount effective to produce an increase in the subject's blood (2?, 5?)-oligoadenylate synthetase (OAS) level, relative to the OAS level in the subject in the absence of interferon-tau.

Abstract: A method for reducing formation of scar tissue by administering interferon-tau (IFN?) to a patient is described. Methods for preventing excessive scar formation, such as keloid formation, and for reducing formation of adhesions by administering IFN? are also described. Interferon-tau is administered systemically or locally in an amount effective to alter the normal processes of scar formation, but without preventing wound healing.

Abstract: Interferon-alpha (IFN?) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFN? analog protein has an amino acid sequence that differs from a native human IFN? interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFN?) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFN? analog protein are also described.

Abstract: Methods of treatment using a high oral dose of an interferon are described. An interferon, such as interferon-alpha, interferon-beta, or interferon-tau, is administered to persons afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation.

Abstract: A method for treating a condition responsive to interferon therapy in a human subject is described. The method includes orally administering interferon-tau to the intestinal tract in an amount effective to produce an increase in the subject's blood 2?, 5?-oligoadenylate synthetase (OAS) level, relative to the OAS level in the subject in the absence of interferon-tau.

Abstract: Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN? are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN? is described. IFN? is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN?.

Abstract: Methods of treating an autoimmune condition by administering IFN? are described. IFN? is administered orally at a dose sufficient to achieve obtain a desired clinical endpoint, such as a reduction in new contrast-enhanced brain lesions in multiple sclerosis patients.

Abstract: Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN? are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN? is described. IFN? is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN?.

Abstract: A method of monitoring treatment of HCV by oral administration of ovine IFN-? is disclosed. The method includes measuring the blood levels of 2?,5?-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-? until a measurable increase in blood 2?,5?-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-?, in a dosage effective to stimulate bloodstream levels of 2?,5?-oligoadenylate synthetase.

Abstract: A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFN?) at a dose sufficient to increase the IL-10 level.